Recent Updates
Recently added Catalysts

REGN20566

Phase 1

Overweight | Small Molecules | Metabolic |Regeneron Pharmaceuticals, Inc.|Trials Updated: Nov 19, 2026

REGN20566 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment304

FDA Designations

No designations recorded

REGN20566 clinical trials

REGN20566 · 1 trial · 2 indications

Phase 1 1
NCT07947966Safety and Drug Concentrations of REGN20566 in Adults With Overweight or ObesityOverweight
NOT YET_RECRUITING304 Analytics
PHASE1NOT YET_RECRUITING
Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity
OverweightUnlock trial analytics

Study Endpoints

Primary Endpoints

Occurrence of Treatment Emergent Adverse Events (TEAEs)
Up to 16 weeks

Part A

Severity of TEAEs
Up to 16 weeks

Part A

Occurrence of TEAEs
Up to 27 weeks

Part B

Secondary Endpoints

Concentration of REGN20566 in serum
Baseline through week 16
Occurrence of Anti-Drug Antibodies (ADA) to REGN20566
Baseline through week 16
Magnitude of ADA to REGN20566
Baseline through week 16
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part AEXPERIMENTAL -
Part BPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
REGN20566DRUGAdministered per the protocol
PlaceboDRUGAdministered per the protocol
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo

Key Inclusion Criteria: 1. Has a body mass index 27-40 kg/m2, inclusive, at screening visit or prior to randomization 2. Healthy volunteers with obesity Key Exclusion Criteria: 1. A self-reported change of body weight \>5 kg within 90 days of screening visit 2. History of type 1 or 2 diabetes, or...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 19, 2026NCT07947966New Trial Detected: Not Yet Recruiting

Frequently asked questions about REGN20566

What is REGN20566?

REGN20566 is an investigational small molecule drug being developed by Regeneron Pharmaceuticals for overweight and obesity. It is in Phase 1 clinical development and has not been approved for any use. It is being studied in adults with overweight or obesity.

What is REGN20566 used for?

REGN20566 is being studied for the treatment of overweight and obesity in adults. Its only listed clinical trial enrolls adults 18 years and older with overweight or obesity. The drug is investigational and has not been approved for any indication.

Who is developing REGN20566?

REGN20566 is being developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. Regeneron is the sponsor of the Phase 1 program evaluating the drug in adults with overweight or obesity.

What phase is REGN20566 in?

REGN20566 is in Phase 1 clinical development. It is an investigational drug and is not FDA approved. Its single registered trial is a Phase 1 study that is not yet recruiting, so clinical development is at an early stage.

What clinical trials is REGN20566 in?

REGN20566 is being studied in one clinical trial, NCT07947966, titled Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity. The Phase 1 trial is not yet recruiting and is planned to enroll 304 participants in a randomized, double-blind, placebo-controlled design.

How is the REGN20566 trial designed?

The Phase 1 trial NCT07947966 is a randomized, double-blind, placebo-controlled study planned to enroll 304 adults aged 18 years and older with overweight or obesity. It is evaluating safety and drug concentrations of REGN20566 and is currently listed as not yet recruiting.